GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer
GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer on February 23 2021 9:00 PM SYDNEY & LAGUNA HILLS, Calif.--(BUSINESS WIRE)--#breastcancerawareness--GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx TM), a leader in molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes. DCISionRT ® is a precision medicine test for women ...
Source: ibtimes.com.au